Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Britannia Life Sciences stock price, quote, forecast and news

BLAB.CN
CA11042D1087
A3DACS

Price

0.06
Today +/-
+0
Today %
+0 %
P

Britannia Life Sciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Britannia Life Sciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Britannia Life Sciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Britannia Life Sciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Britannia Life Sciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Britannia Life Sciences Stock Price History

DateBritannia Life Sciences Price
9/27/20240.06 undefined
9/26/20240.06 undefined
9/25/20240.06 undefined
9/23/20240.06 undefined
9/20/20240.06 undefined
9/19/20240.06 undefined
9/18/20240.04 undefined
9/17/20240.06 undefined
9/16/20240.06 undefined
9/16/20240.06 undefined
9/13/20240.05 undefined
9/12/20240.05 undefined
9/11/20240.05 undefined
9/10/20240.05 undefined
9/9/20240.05 undefined
9/9/20240.05 undefined
9/6/20240.05 undefined
9/5/20240.05 undefined
9/4/20240.05 undefined
9/3/20240.05 undefined
9/3/20240.05 undefined
8/30/20240.05 undefined

Britannia Life Sciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Britannia Life Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Britannia Life Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Britannia Life Sciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Britannia Life Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Britannia Life Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Britannia Life Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Britannia Life Sciences’s growth potential.

Britannia Life Sciences Revenue, EBIT and net profit per share

DateBritannia Life Sciences RevenueBritannia Life Sciences EBITBritannia Life Sciences Net Income
20247.57 M undefined1.29 M undefined-4.77 M undefined
20236.4 M undefined994,090 undefined5.08 M undefined
20227.3 M undefined1.62 M undefined-15.46 M undefined
202031,790 undefined-1.01 M undefined-3.2 M undefined
2019974,270 undefined-5.2 M undefined-7.13 M undefined
2018186,030 undefined-5.29 M undefined-11.86 M undefined
20170 undefined-1.99 M undefined-2.39 M undefined
20160 undefined-576,970 undefined-1.11 M undefined
20159,150 undefined-1.94 M undefined-3.29 M undefined

Britannia Life Sciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (k)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201520162017201820192020202220232024
000000767
--------14.2916.67
------71.4366.6757.14
000000544
-1,0000-1,000-5,000-5,000-1,0001,00001,000
------14.29-14.29
-3-1-2-11-7-3-155-4
--66.67100.00450.00-36.36-57.14400.00-133.33-180.00
0.170.221.3255.815.9109.5162.14162.25
---------
Details

Keystats

ⓘ

Revenue and Growth

The Britannia Life Sciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Britannia Life Sciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (k)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201520162017201820192020202220232024
                 
00.131.073.880.250.071.632.61.32
0.010.040.160.440.070.11.791.61.21
000000000
000214.1158.383.1400184.36
0.0700.010.12.070.010.060.020.01
0.090.181.244.632.460.183.484.222.73
285.71265.7819.44116.33115.8477.88545.8452.38721.28
00000001.270.73
000000000
001.90.20017.060.230.3
0000.590.590017.3817.78
000119.200000
0.290.271.921.020.710.0817.6119.3319.53
0.370.443.165.653.160.2621.0923.5522.26
                 
14.815.0419.0324.86252517.0717.1117.11
3.834.585.135.987.388.960.160.163.41
-21.34-23.1-24.86-34.31-42.41-47.19-14.39-9.08-17.36
000-15.67-44.7926.41-1,483.35-1,157.1-715.06
000000000
-2.71-3.48-0.7-3.49-10.08-13.21.357.022.44
1.021.260.912.312.152.793.22.553
467.252.0119.4245.2700180.4100
000000005.27
0000004.890.240.25
1.60.070.150.369.610.630.051.81.98
3.081.331.082.7211.7513.428.324.610.5
01.71.614.761.480.040.256.365.06
00000078.39103.9229.32
00.891.171.670.0106.951.420
02.592.786.421.490.047.297.895.09
3.083.923.859.1413.2413.4615.6112.4915.59
0.370.443.165.653.160.2616.9619.5118.03
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Britannia Life Sciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Britannia Life Sciences's financial health and stability.

Assets

Britannia Life Sciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Britannia Life Sciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Britannia Life Sciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Britannia Life Sciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20152016201720182019202020222023
-3-1-2-11-7-3-135
00000000
00000000
0000-1000
10071216-4
00000000
00000000
-10-2-3-7021
00000000
0000000-3
0000000-2
00000000
00033-1-12
10330000
103730-22
000001,00000
00000000
-1002-3000
-1.75-0.35-2.26-4.68-7.18-0.212.710.87
00000000

Britannia Life Sciences stock margins

The Britannia Life Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Britannia Life Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Britannia Life Sciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Britannia Life Sciences's sales revenue. A higher gross margin percentage indicates that the Britannia Life Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Britannia Life Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Britannia Life Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Britannia Life Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Britannia Life Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Britannia Life Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Britannia Life Sciences Margin History

Britannia Life Sciences Gross marginBritannia Life Sciences Profit marginBritannia Life Sciences EBIT marginBritannia Life Sciences Profit margin
202464.12 %17.01 %-62.99 %
202372.43 %15.52 %79.39 %
202272.08 %22.13 %-211.76 %
202062.91 %-3,179.65 %-10,079.52 %
201934.71 %-534.22 %-731.5 %
201873.46 %-2,846.14 %-6,373.26 %
201764.12 %0 %0 %
201664.12 %0 %0 %
2015100 %-21,215.19 %-35,914.65 %

Britannia Life Sciences Stock Sales Revenue, EBIT, Earnings per Share

The Britannia Life Sciences earnings per share therefore indicates how much revenue Britannia Life Sciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Britannia Life Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Britannia Life Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Britannia Life Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Britannia Life Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Britannia Life Sciences Revenue, EBIT and net profit per share

DateBritannia Life Sciences Sales per ShareBritannia Life Sciences EBIT per shareBritannia Life Sciences Earnings per Share
20240.05 undefined0.01 undefined-0.03 undefined
20230.04 undefined0.01 undefined0.03 undefined
20220.07 undefined0.01 undefined-0.14 undefined
20200.01 undefined-0.17 undefined-0.54 undefined
20190.17 undefined-0.9 undefined-1.23 undefined
20180.04 undefined-1.06 undefined-2.37 undefined
20170 undefined-1.51 undefined-1.81 undefined
20160 undefined-2.58 undefined-4.96 undefined
20150.05 undefined-11.13 undefined-18.84 undefined

Britannia Life Sciences business model

Britannia Life Sciences is one of the most popular companies on Eulerpool.com.

Britannia Life Sciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Britannia Life Sciences historical P/E ratio, EBIT, and P/S ratio.

Britannia Life Sciences shares outstanding

The number of shares was Britannia Life Sciences in 2023 — This indicates how many shares 162.142 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Britannia Life Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Britannia Life Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Britannia Life Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Britannia Life Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Britannia Life Sciences Stock splits

In Britannia Life Sciences's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Britannia Life Sciences.

Britannia Life Sciences list of shareholders

%
Name
Stocks
Change
Date
24.23554 % Shippen (Peter James)37,053,231-350,0008/24/2023
2.62974 % Secord (Scott Lawrence)4,020,55008/24/2023
12.16577 % Bowes-Cavanagh (Mark)18,600,00008/24/2023
0.98315 % Purpose Investments Inc.1,503,12202/29/2024
1

Britannia Life Sciences Executives and Management Board

Mr. Scott Secord
Britannia Life Sciences Executive Chairman of the Board, Chief Executive Officer (since 2018)
Compensation 360,000
Mr. Robert Lelovic
Britannia Life Sciences Chief Financial Officer
Compensation 180,000
Mr. Ashwath Mehra
Britannia Life Sciences Independent Director
1

Most common questions regarding Britannia Life Sciences

What is the P/E ratio of Britannia Life Sciences 2024?

The Britannia Life Sciences P/E ratio is -2.04.

What is the P/S ratio of Britannia Life Sciences 2024?

The Britannia Life Sciences P/S ratio is 1.29.

What is the AlleAktien quality score of Britannia Life Sciences?

The AlleAktien quality score for Britannia Life Sciences is 1/10.

What is the revenue of Britannia Life Sciences 2024?

The Britannia Life Sciences revenue is 7.57 M CAD.

How high is the profit of Britannia Life Sciences 2024?

The Britannia Life Sciences profit is -4.77 M CAD.

What is the business model of Britannia Life Sciences

No history available for Britannia Life Sciences.

What is the Britannia Life Sciences dividend?

Britannia Life Sciences pays a dividend of 0 CAD distributed over payouts per year.

How often does Britannia Life Sciences pay dividends?

The dividend cannot currently be calculated for Britannia Life Sciences or the company does not pay out a dividend.

What is the Britannia Life Sciences ISIN?

The ISIN of Britannia Life Sciences is CA11042D1087.

What is the Britannia Life Sciences WKN?

The WKN of Britannia Life Sciences is A3DACS.

What is the Britannia Life Sciences ticker?

The ticker of Britannia Life Sciences is BLAB.CN.

How much dividend does Britannia Life Sciences pay?

Over the past 12 months, Britannia Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Britannia Life Sciences is expected to pay a dividend of 0 CAD.

What is the dividend yield of Britannia Life Sciences?

The current dividend yield of Britannia Life Sciences is .

When does Britannia Life Sciences pay dividends?

Britannia Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Britannia Life Sciences?

Britannia Life Sciences paid dividends every year for the past 0 years.

What is the dividend of Britannia Life Sciences?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Britannia Life Sciences located?

Britannia Life Sciences is assigned to the '-' sector.

Wann musste ich die Aktien von Britannia Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Britannia Life Sciences from 9/29/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Britannia Life Sciences pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Britannia Life Sciences in the year 2023?

In the year 2023, Britannia Life Sciences distributed 0 CAD as dividends.

In which currency does Britannia Life Sciences pay out the dividend?

The dividends of Britannia Life Sciences are distributed in CAD.

All fundamentals about Britannia Life Sciences

Our stock analysis for Britannia Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Britannia Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.